Conexeu Sciences Inc. closed a private placement on October 15, 2026, raising gross proceeds through the sale of unregistered equity securities. The company disclosed the transaction in a Form 8-K filed with the U.S. Securities and Exchange Commission, detailing the issuance of shares, units, and special warrants to accredited investors. This financing activity triggered a mandatory disclosure under Item 3.02 of Form 8-K because the aggregate issuance exceeded 5% of the company's issued and outstanding common stock since its last periodic report.
The primary component of the offering involved the sale of 1,333,333 units to three accredited investors at a price of $3.00 per unit, generating gross proceeds of $3,999,999. Each unit consists of one share of common stock and one warrant to purchase an additional share at $3.00 per share, exercisable for 24 months from issuance. The company stated it intends to use these proceeds for working capital and general corporate purposes. The securities were issued under exemptions from registration requirements provided by Rule 506(b) of Regulation D for U.S. investors and Rule 903(b) of Regulation S for non-U.S. investors. Both the shares and warrants are classified as restricted securities under Rule 144(a)(3) of the Securities Act.
A portion of the same private placement included subscriptions from members of management and the Board of Directors for 83,334 units at $3.00 per unit, totaling $250,002. However, these units have not yet been issued, and the funds are currently held in escrow. The release of these funds and the issuance of the corresponding securities are pending approval by Conexeu Sciences stockholders as required under Nasdaq Listing Rule 5635(c). If stockholder approval is not obtained, the escrowed funds will be returned to the subscribers, and no shares or warrants will be issued.
Additionally, the company issued 250,000 special warrants to two Canadian accredited investors at $3.00 per warrant for gross proceeds of $750,000. Unlike standard units, these special warrants will automatically convert into one share and one warrant each upon the earlier of two conditions: the receipt of a final Canadian prospectus qualifying the distribution in British Columbia by the British Columbia Securities Commission, or February 16, 2027. These securities were also issued under Rule 903(b) of Regulation S and are considered restricted securities.
As part of the agreement for the October 15 closing, Conexeu Sciences committed to file a Form S-1 registration statement with the SEC to cover the resale of shares and warrant shares on a continuous basis pursuant to Rule 415. The company must file this statement no later than 35 calendar days following October 15, 2026. If the filing deadline is missed, the company is required to pay cash liquidated damages equal to 2.0% of the aggregate subscription price paid by each affected subscriber.
The filings indicate that Conexeu Sciences is an emerging growth company incorporated in Nevada with its principal executive offices in Reno. The company's common stock trades on The Nasdaq Stock Market LLC under the ticker symbol CNXU.